Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.

This article explores the challenges faced by cystic fibrosis (CF) patients in low- to middle-income countries in accessing the triple combination therapy of elexacaftor, tezacaftor, and ivacaftor (ETI). The therapy is currently expensive and not widely available due to regulatory approval and cost issues. The authors propose a strategy using pharmacokinetic enhancement to reduce the cost of treatment, which involves the use of boosting agents like ritonavir. They also suggest the potential use of generic ETI formulations. Preliminary data from South Africa shows promising results, but further clinical trials are needed to evaluate the effectiveness, safety, and cost-effectiveness of this approach. [Extracted from the article]